WO2009124176A8 - Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions - Google Patents

Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions Download PDF

Info

Publication number
WO2009124176A8
WO2009124176A8 PCT/US2009/039272 US2009039272W WO2009124176A8 WO 2009124176 A8 WO2009124176 A8 WO 2009124176A8 US 2009039272 W US2009039272 W US 2009039272W WO 2009124176 A8 WO2009124176 A8 WO 2009124176A8
Authority
WO
WIPO (PCT)
Prior art keywords
endothelial
cyclopentadione
substituted
attenuated
inflammation
Prior art date
Application number
PCT/US2009/039272
Other languages
French (fr)
Other versions
WO2009124176A1 (en
Inventor
Veera Konda
Anu Desai
Matthew L. Tripp
Gary Darland
Joseph Lamb
Jeffrey S. Bland
Dennis A. Emma
Original Assignee
Metaproteomics, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics, Llc. filed Critical Metaproteomics, Llc.
Priority to CA2720546A priority Critical patent/CA2720546A1/en
Priority to JP2011503164A priority patent/JP2011516492A/en
Priority to EP09728126A priority patent/EP2268600A4/en
Priority to AU2009231723A priority patent/AU2009231723B2/en
Priority to CN2009801191272A priority patent/CN102066303A/en
Priority to NZ588927A priority patent/NZ588927A/en
Priority to MX2010010791A priority patent/MX2010010791A/en
Publication of WO2009124176A1 publication Critical patent/WO2009124176A1/en
Publication of WO2009124176A8 publication Critical patent/WO2009124176A8/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/707Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a three- to five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Abstract

Compositions and methods for reducing cardiovascular risk utilizing substituted 1,3- cyclopentadione compounds are described.
PCT/US2009/039272 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions WO2009124176A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2720546A CA2720546A1 (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
JP2011503164A JP2011516492A (en) 2008-04-02 2009-04-02 Attenuation of endothelial inflammation and endothelium-monocyte interaction by substituted 1,3-cyclopentadione
EP09728126A EP2268600A4 (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
AU2009231723A AU2009231723B2 (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
CN2009801191272A CN102066303A (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
NZ588927A NZ588927A (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
MX2010010791A MX2010010791A (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4163108P 2008-04-02 2008-04-02
US61/041,631 2008-04-02

Publications (2)

Publication Number Publication Date
WO2009124176A1 WO2009124176A1 (en) 2009-10-08
WO2009124176A8 true WO2009124176A8 (en) 2010-11-18

Family

ID=41135936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039272 WO2009124176A1 (en) 2008-04-02 2009-04-02 Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions

Country Status (10)

Country Link
US (1) US20100222262A1 (en)
EP (1) EP2268600A4 (en)
JP (1) JP2011516492A (en)
KR (1) KR20110010603A (en)
CN (1) CN102066303A (en)
AU (1) AU2009231723B2 (en)
CA (1) CA2720546A1 (en)
MX (1) MX2010010791A (en)
NZ (1) NZ588927A (en)
WO (1) WO2009124176A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US20110275721A1 (en) * 2008-12-10 2011-11-10 Metaproteomics, Llc Method for the purification of substituted cyclopent-2-en-1-one congeners and substituted 1,3-cyclopentadione congeners from a complex mixture using countercurrent separation
AU2013290297B2 (en) * 2012-07-09 2017-11-02 Kindex Pharmaceuticals, Inc. Tetrahydro-isohumulone derivatives, methods of making and using
GB201611738D0 (en) * 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933919A (en) * 1964-12-15 1976-01-20 Geoffrey Wilkinson Hydroformylation of mono-α-olefins and mono-α-acetylenes
US3451821A (en) * 1965-03-01 1969-06-24 Kalamazoo Spice Extract Co Increasing the utilization of hops and improving flavor control of malt beverages and the like
GB1140545A (en) * 1965-03-01 1969-01-22 Kalamazoo Spice Extract Co Hop flavours for malt beverages and the like
US3536495A (en) * 1968-03-13 1970-10-27 Miller Brewing Ammonia complexes of hop alpha acids and modified alpha acids
US3975442A (en) * 1970-12-09 1976-08-17 Hoffmann-La Roche Inc. 2-Alkyl-2-(3-oxoalkyl)-1,3-cyclopentadiones
US3720517A (en) * 1970-12-21 1973-03-13 Hamm T Brewing Co Preparation of a fermented malt champagne
US3932603A (en) * 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
US3965188A (en) * 1972-01-10 1976-06-22 Miller Brewing Company Hop extract process and product
JPS4926272A (en) * 1972-07-05 1974-03-08
CH617326A5 (en) * 1975-12-04 1980-05-30 Siegfried Ag
US4170638A (en) * 1976-11-05 1979-10-09 S. S. Steiner, Inc. Method for producing a deodorant
US4148873A (en) * 1976-11-05 1979-04-10 S. S. Steiner, Inc. Method for treating the skin with extracts of hops
US4123561A (en) * 1977-02-01 1978-10-31 S.S. Steiner, Inc. Method for processing hops for brewing
US4401684A (en) * 1981-10-01 1983-08-30 Australian Hop Marketers Pty. Ltd. Preservation of hops utilizing ascorbic acid
US4389421A (en) * 1981-10-30 1983-06-21 Busch Industrial Products Corporation Method for controlling light stability in malt beverages and product thereof
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4590296A (en) * 1984-01-25 1986-05-20 Miller Brewing Company Process for separation of beta-acids from extract containing alpha-acids and beta-acids
US4644084A (en) * 1984-01-25 1987-02-17 Miller Brewing Company Preparation of tetrahydroisohumulones
DE3513169A1 (en) * 1985-04-12 1986-10-16 Hopstabil Hopfenverarbeitungs-Gesellschaft mbH, 8069 Wolnzach METHOD FOR PRODUCING ISOHUMULONES
US4767640A (en) * 1985-10-29 1988-08-30 Miller Brewing Company Light stable hop extracts and method of preparation
US4692280A (en) * 1986-12-01 1987-09-08 The United States Of America As Represented By The Secretary Of Commerce Purification of fish oils
US5041300A (en) * 1987-04-03 1991-08-20 Kalamazoo Holdings, Inc. Hop flavor which is odor forming impurity free
DE3712986A1 (en) * 1987-04-16 1988-10-27 Marbert Gmbh MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT
US4857554A (en) * 1987-08-17 1989-08-15 Georgios Kallimanis Method for the treatment of psoriasis
US5082975A (en) * 1988-08-15 1992-01-21 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
US5013571A (en) * 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
EP0474892B1 (en) * 1990-09-10 1996-04-10 Fromm, Mayer-Bass Limited Process for the isomerisation of humulone in a carbon dioxide-hop extract and method for extracting the isohumulone
TW199905B (en) * 1992-02-03 1993-02-11 J E Siebel Sons Company Inc Method and composition for enhancing foam properties of fermented malt beverages
WO1994003192A1 (en) * 1992-07-29 1994-02-17 Drymed A/S Composition comprising fertilized shell eggs
US5286506A (en) * 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
US5296637A (en) * 1992-12-31 1994-03-22 Kalamazoo Holdings, Inc. Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
JP2677762B2 (en) * 1994-04-08 1997-11-17 株式会社神戸製鋼所 Oil-cooled compressor
EP0677289B1 (en) * 1994-04-12 1999-01-13 Hoechst Marion Roussel, Ltd. Pharmaceutical composition for treating osteoporosis
IN184685B (en) * 1996-02-14 2000-09-23 Nat Inst Immunology
US5827895A (en) * 1996-02-27 1998-10-27 Regents Of The University Of Minnesota Hexahydrolupulones useful as anticancer agents
US6020019A (en) * 1996-03-26 2000-02-01 Miller Brewing Company Hydrogenation of hop soft resins using CO2
US6589994B1 (en) * 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5968539A (en) * 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
US6224871B1 (en) * 1998-03-11 2001-05-01 Reliv International, Inc. Dietary supplement for nutritionally promoting healthy joint function
US5919813C1 (en) * 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2147538B1 (en) * 1999-01-29 2001-04-01 Revlon Consumer Prod Corp A CAPILLARY LOTION WITH IMPROVED PROPERTIES IN ITS HAIR PROTECTIVE AND PREVENTIVE ACTION OF HIS FALL, AND REDUCTION OF THE EXTERNAL EFFECTS OF ANDROGENETIC ALOPECIA AND WITH THAT OF THE HAIR FALL.
US6801860B1 (en) * 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US6462029B1 (en) * 1999-02-23 2002-10-08 Econugenics Compositions and methods for treating mammals with modified alginates and modified pectins
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6210701B1 (en) * 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
US6129907A (en) * 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
WO2001021165A1 (en) * 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) * 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
US6200594B1 (en) * 1999-12-29 2001-03-13 Vital Dynamics, Inc. Breast-enhancing, herbal compositions and methods of using same
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6583322B1 (en) * 2000-02-25 2003-06-24 Kalamazoo Holdings, Inc. Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations
KR20030005252A (en) * 2000-03-31 2003-01-17 니신 오일 밀스 가부시키가이샤 External preparation for the skin and beautifying agents
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US6908630B2 (en) * 2000-08-01 2005-06-21 Metaproteomics, Llc Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
FR2815227B1 (en) * 2000-10-17 2003-04-11 Schwartz Laboratoires Robert ANTI-STRESS COMPOSITION FOR PRIMARY INCORPORATION IN NUTRITIONAL VEHICLES
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US7078062B2 (en) * 2001-01-17 2006-07-18 S.S. Steiner, Inc. Hop-based udder and teat dips and washes
US20030035851A1 (en) * 2001-02-08 2003-02-20 Sophie Chen Anti-cancer agents and method of use thereof
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
US20030003212A1 (en) * 2001-06-13 2003-01-02 Givaudan Sa Taste modifiers
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
EP1446136B1 (en) * 2001-10-26 2010-09-29 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7108868B2 (en) * 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
DE20314366U1 (en) * 2002-09-16 2004-05-19 Perkins Engines Co. Ltd. Cylinder head for internal combustion engine, e.g. three-cylinder diesel engine, has top deck and multiple integrally cast rocker shaft pedestals having opposing side walls to correctly space adjacent rocker arms on each side of pedestal
MXPA05004288A (en) * 2002-10-21 2005-08-02 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response.
US7144590B2 (en) * 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
KR20060118552A (en) * 2003-12-16 2006-11-23 바젤 폴리올레핀 게엠베하 Monocyclopentadienyl complexes
CA2554387A1 (en) * 2004-01-28 2005-08-11 Merck & Co., Inc. Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20070065456A1 (en) * 2005-09-20 2007-03-22 Woods Cindy J Nutritional supplements
JP2009518439A (en) * 2005-12-09 2009-05-07 メタプロテオミクス,エルエルシー Protein kinase regulation by hops and acacia products
US8062898B2 (en) * 2006-10-20 2011-11-22 The Board Of Trustees Of The University Of Illinois Selection and rational development of solvent systems in counter-current chromatograph

Also Published As

Publication number Publication date
WO2009124176A1 (en) 2009-10-08
NZ588927A (en) 2013-02-22
KR20110010603A (en) 2011-02-01
EP2268600A4 (en) 2012-03-21
AU2009231723A1 (en) 2009-10-08
MX2010010791A (en) 2011-03-04
US20100222262A1 (en) 2010-09-02
CA2720546A1 (en) 2009-10-08
CN102066303A (en) 2011-05-18
EP2268600A1 (en) 2011-01-05
AU2009231723B2 (en) 2014-04-17
JP2011516492A (en) 2011-05-26

Similar Documents

Publication Publication Date Title
EP3284772B8 (en) Thioethers, methods for their preparation, and compositions including such thioethers
IL232093A0 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010059531A3 (en) Alpha-keto peracids and methods for producing and using the same
EP2499195A4 (en) Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
WO2009014891A3 (en) Increasing plant vigor
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
WO2009120810A3 (en) Neurodegenerative disorders
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
IL207066A0 (en) Iap inhibitor compounds, compositions comprising the same and uses thereof
EP2291450A4 (en) Polymeric compositions, methods of making the same, and articles prepared from the same
WO2010072420A3 (en) Compositions comprising hemp oil for treating topical diseases, especially hand-foot syndrome
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof
WO2009124176A8 (en) Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
HK1149770A1 (en) Compositions, methods and kits
ZA201007330B (en) Novel pyriproxyfen compositions
BRPI0906343A2 (en) pentafluorethane, tetraflueoretane and n-butane compositions.
IL208262A0 (en) Hydroxyquinoxalinecar boxamide derivatives, compositions comprising the same and uses thereof
WO2009088939A3 (en) Compositions and methods for treating neurodegenerative diseases
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods
WO2009106258A8 (en) Diflufenican-containing herbicidal combinations
WO2011041318A3 (en) Compatibilizer blend for polymeric compositions
WO2010111421A3 (en) Isoform nell-1 peptide
WO2011006097A3 (en) Methods For Treating Toxicity
WO2009093189A3 (en) Peptides, compositions, and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980119127.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09728126

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/010791

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2720546

Country of ref document: CA

Ref document number: 2011503164

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009231723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009728126

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009231723

Country of ref document: AU

Date of ref document: 20090402

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 588927

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 20107024543

Country of ref document: KR

Kind code of ref document: A